If You Invested in Accuray Incorp (ARAY)

Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures, sells and supports precise radiation treatment solutions. The company focuses on radiation therapy systems that are designed to treat multiple types of cancer and tumors throughout the body with high precision. According to available information, Accuray’s technology includes the CyberKnife System, which is used to deliver radiation treatments with sub-millimeter accuracy.

The CyberKnife Systems automatically track, detect and correct for tumor and patient movement in real time during a procedure. This capability is designed to enable the delivery of precise, high-dose radiation while patients breathe normally, without manual user intervention. By focusing on accurate targeting and motion management, Accuray aims to make radiation therapy an option for even complex cases and to simplify treatment for more commonly treatable conditions.

Business focus and technology

Accuray describes itself as being committed to expanding the potential of radiation therapy to improve as many lives as possible. The company states that it invents unique, market-changing solutions designed to deliver radiation treatments for very complex cases while making commonly treatable cases easier to manage. Its work spans oncology, neuro-radiosurgery and related areas, with an emphasis on continuous innovation in radiation therapy.

Beyond CyberKnife, Accuray references a helical radiation treatment delivery platform and the Radixact Treatment Delivery System. The company has introduced the Accuray Stellar Solution, described as a configuration of the Radixact system initially for the U.S. market. Accuray indicates that this solution is intended to support adaptive radiotherapy and a range of delivery modalities, such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and surface-guided radiation therapy (SGRT), for standard indications including breast, prostate, lung, and head and neck cancers, as well as complex treatments such as total marrow irradiation.

Accuray also highlights technologies such as Synchrony motion tracking and correction, PreciseART for offline adaptive protocols, and an online-adaptive ready interface. These tools are described as forming a foundation for adaptive care that can evolve with each patient’s needs. ClearRT helical kVCT imaging is identified as a core imaging technology designed to acquire high-resolution images to support precise planning and delivery.

Industry and collaborations

Accuray operates within the surgical and medical instrument manufacturing industry, with a sector classification in manufacturing. Within this context, the company focuses on radiation therapy systems and related software and services. It reports that it partners with clinicians and administrators to help them deliver radiation treatments and support patients in returning to their lives more quickly after therapy.

The company has announced a memorandum of understanding with the University of Wisconsin School of Medicine and Public Health to advance online adaptive radiotherapy on its helical radiation treatment delivery platform. The collaboration is intended to cover clinical research, education and training, and adaptive technology development related to online adaptive radiotherapy. Accuray notes that the origins of the TomoTherapy System, a helical radiation delivery platform, began at the University of Wisconsin-Madison, and that the company has continued to evolve this platform to enhance precision, accuracy, quality, speed, versatility and workflow efficiencies.

Global presence and clinical use

Accuray states that it is headquartered in Madison, Wisconsin, with facilities worldwide. It reports that its systems, including CyberKnife and Radixact, are installed in hospitals and markets globally. For example, the company has highlighted the use of the CyberKnife S7 System in Melbourne, Australia, through a collaboration with 5D Clinics and Icon Group. That collaboration aims to increase access to stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatments in Australia, with a focus on enabling patients to receive advanced radiation treatments closer to home.

In that context, Accuray describes the CyberKnife S7 System as combining speed, precision and artificial intelligence to track and automatically adapt for movement during treatment. The system is described as enabling delivery of very high doses of radiation in a small number of outpatient sessions, with sub-millimeter precision and accuracy, which can reduce the number of treatment visits compared with conventional fractionation.

Strategic and organizational transformation

Accuray has announced a comprehensive strategic, operational and organizational transformation plan. The first phase of this plan is described as being designed to realign the organization to produce sharper accountability, tighter cost control and faster execution. Elements of the plan include streamlining the commercial structure, centralizing and globalizing core functions, elevating global heads of service and product development to report directly to the chief executive officer, and optimizing the company’s workforce and footprint.

As part of this transformation, Accuray reports that it is outsourcing selected non-core activities, rationalizing facilities, implementing programs to improve direct and indirect spending efficiency, and reallocating engineering resources to focus on high-return programs and integration of third-party solutions. The company has disclosed that these actions include a reduction of approximately 15% of its global workforce and associated restructuring charges. It expects these initiatives to improve operating profitability on an annualized basis once fully implemented.

Capital structure and governance

Accuray has reported entering into a financing agreement and subsequent amendments with TCW Asset Management Company LLC and other lenders. An 8-K filing describes amendments that adjust the calculation of liquidity, modify conditions related to a delayed draw term loan facility, and change the timing of financial covenant testing. In connection with these amendments, Accuray has issued warrants to purchase shares of its common stock to certain lenders, with specified exercise prices, terms and anti-dilution provisions.

The company has also reported on its corporate governance and stockholder matters through proxy statements and 8-K filings. For example, stockholders approved a 2026 Equity Incentive Plan and cast advisory votes on executive compensation and the appointment of the independent registered public accounting firm. The company has disclosed board and management changes, including the appointment of a new chief executive officer and changes in board composition, as part of its broader transformation efforts.

Financial reporting

Accuray files annual, quarterly and current reports with the U.S. Securities and Exchange Commission. It has reported financial results for fiscal years and quarters, including information on product and service revenue, gross profit, operating expenses, net income or loss, adjusted EBITDA, orders and backlog, and cash and debt balances. The company uses non-GAAP financial measures such as adjusted EBITDA and provides reconciliations to the most directly comparable GAAP measures in its filings.

Accuray’s financial disclosures also discuss factors that may affect its performance, including macroeconomic conditions, supply chain dynamics, tariffs, international operations, regulatory approvals and joint venture arrangements. These factors are described in its risk factor disclosures and forward-looking statements sections in SEC filings and press releases.

Position within radiation oncology

Within radiation oncology, Accuray positions its systems as tools to enable personalized and precise radiation treatments. The company emphasizes adaptive radiotherapy, motion management, and integrated imaging as key aspects of its technology. Its collaborations, product launches and clinical use cases, such as the introduction of the Accuray Stellar Solution and the expansion of CyberKnife and Radixact systems into new hospitals and markets, are presented as part of its effort to support clinicians in delivering radiation therapy across a spectrum of cancer indications.